Table of Content

1 Platinum-based Antineoplastic Market Overview
1.1 Product Overview and Scope of Platinum-based Antineoplastic
1.2 Platinum-based Antineoplastic Segment by Type
1.2.1 Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2034)
1.2.2 Cisplatin
1.2.3 Carboplatin
1.2.4 Nedaplatin
1.2.5 Oxaliplatin
1.2.6 Lobaplatin
1.2.7 Cycloplatin
1.3 Platinum-based Antineoplastic Segment by Application
1.3.1 Global Platinum-based Antineoplastic Market Value by Application: (2024-2034)
1.3.2 Combination Therapy
1.3.3 Monotherapy
1.3.4 Targeted Therapy
1.4 Global Platinum-based Antineoplastic Market Size Estimates and Forecasts
1.4.1 Global Platinum-based Antineoplastic Revenue 2024-2034
1.4.2 Global Platinum-based Antineoplastic Sales 2024-2034
1.4.3 Global Platinum-based Antineoplastic Market Average Price (2024-2034)
1.5 Assumptions and Limitations
2 Platinum-based Antineoplastic Market Competition by Manufacturers
2.1 Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2024-2024)
2.2 Global Platinum-based Antineoplastic Revenue Market Share by Manufacturers (2024-2024)
2.3 Global Platinum-based Antineoplastic Average Price by Manufacturers (2024-2024)
2.4 Global Platinum-based Antineoplastic Industry Ranking 2021 VS 2022 VS 2024
2.5 Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application
2.7 Platinum-based Antineoplastic Market Competitive Situation and Trends
2.7.1 Platinum-based Antineoplastic Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Platinum-based Antineoplastic Players Market Share by Revenue
2.7.3 Global Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Platinum-based Antineoplastic Retrospective Market Scenario by Region
3.1 Global Platinum-based Antineoplastic Market Size by Region: 2024 Versus 2022 Versus 2034
3.2 Global Platinum-based Antineoplastic Global Platinum-based Antineoplastic Sales by Region: 2024-2034
3.2.1 Global Platinum-based Antineoplastic Sales by Region: 2024-2024
3.2.2 Global Platinum-based Antineoplastic Sales by Region: 2024-2034
3.3 Global Platinum-based Antineoplastic Global Platinum-based Antineoplastic Revenue by Region: 2024-2034
3.3.1 Global Platinum-based Antineoplastic Revenue by Region: 2024-2024
3.3.2 Global Platinum-based Antineoplastic Revenue by Region: 2024-2034
3.4 North America Platinum-based Antineoplastic Market Facts & Figures by Country
3.4.1 North America Platinum-based Antineoplastic Market Size by Country: 2024 VS 2022 VS 2034
3.4.2 North America Platinum-based Antineoplastic Sales by Country (2024-2034)
3.4.3 North America Platinum-based Antineoplastic Revenue by Country (2024-2034)
3.4.4 United States
3.4.5 Canada
3.5 Europe Platinum-based Antineoplastic Market Facts & Figures by Country
3.5.1 Europe Platinum-based Antineoplastic Market Size by Country: 2024 VS 2022 VS 2034
3.5.2 Europe Platinum-based Antineoplastic Sales by Country (2024-2034)
3.5.3 Europe Platinum-based Antineoplastic Revenue by Country (2024-2034)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Platinum-based Antineoplastic Market Facts & Figures by Country
3.6.1 Asia Pacific Platinum-based Antineoplastic Market Size by Country: 2024 VS 2022 VS 2034
3.6.2 Asia Pacific Platinum-based Antineoplastic Sales by Country (2024-2034)
3.6.3 Asia Pacific Platinum-based Antineoplastic Revenue by Country (2024-2034)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Platinum-based Antineoplastic Market Facts & Figures by Country
3.7.1 Latin America Platinum-based Antineoplastic Market Size by Country: 2024 VS 2022 VS 2034
3.7.2 Latin America Platinum-based Antineoplastic Sales by Country (2024-2034)
3.7.3 Latin America Platinum-based Antineoplastic Revenue by Country (2024-2034)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Platinum-based Antineoplastic Market Facts & Figures by Country
3.8.1 Middle East and Africa Platinum-based Antineoplastic Market Size by Country: 2024 VS 2022 VS 2034
3.8.2 Middle East and Africa Platinum-based Antineoplastic Sales by Country (2024-2034)
3.8.3 Middle East and Africa Platinum-based Antineoplastic Revenue by Country (2024-2034)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Platinum-based Antineoplastic Sales by Type (2024-2034)
4.1.1 Global Platinum-based Antineoplastic Sales by Type (2024-2024)
4.1.2 Global Platinum-based Antineoplastic Sales by Type (2024-2034)
4.1.3 Global Platinum-based Antineoplastic Sales Market Share by Type (2024-2034)
4.2 Global Platinum-based Antineoplastic Revenue by Type (2024-2034)
4.2.1 Global Platinum-based Antineoplastic Revenue by Type (2024-2024)
4.2.2 Global Platinum-based Antineoplastic Revenue by Type (2024-2034)
4.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Type (2024-2034)
4.3 Global Platinum-based Antineoplastic Price by Type (2024-2034)
5 Segment by Application
5.1 Global Platinum-based Antineoplastic Sales by Application (2024-2034)
5.1.1 Global Platinum-based Antineoplastic Sales by Application (2024-2024)
5.1.2 Global Platinum-based Antineoplastic Sales by Application (2024-2034)
5.1.3 Global Platinum-based Antineoplastic Sales Market Share by Application (2024-2034)
5.2 Global Platinum-based Antineoplastic Revenue by Application (2024-2034)
5.2.1 Global Platinum-based Antineoplastic Revenue by Application (2024-2024)
5.2.2 Global Platinum-based Antineoplastic Revenue by Application (2024-2034)
5.2.3 Global Platinum-based Antineoplastic Revenue Market Share by Application (2024-2034)
5.3 Global Platinum-based Antineoplastic Price by Application (2024-2034)
6 Key Companies Profiled
6.1 Pfizer
6.1.1 Pfizer Corporation Information
6.1.2 Pfizer Description and Business Overview
6.1.3 Pfizer Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.1.4 Pfizer Platinum-based Antineoplastic Product Portfolio
6.1.5 Pfizer Recent Developments/Updates
6.2 AstraZeneca
6.2.1 AstraZeneca Corporation Information
6.2.2 AstraZeneca Description and Business Overview
6.2.3 AstraZeneca Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.2.4 AstraZeneca Platinum-based Antineoplastic Product Portfolio
6.2.5 AstraZeneca Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.3.4 Roche Platinum-based Antineoplastic Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Sanofi Platinum-based Antineoplastic Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.5.4 Bristol-Myers Squibb Platinum-based Antineoplastic Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Asta Medica GmbH
6.6.1 Asta Medica GmbH Corporation Information
6.6.2 Asta Medica GmbH Description and Business Overview
6.6.3 Asta Medica GmbH Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.6.4 Asta Medica GmbH Platinum-based Antineoplastic Product Portfolio
6.6.5 Asta Medica GmbH Recent Developments/Updates
6.7 Simcere Pharmaceutical
6.6.1 Simcere Pharmaceutical Corporation Information
6.6.2 Simcere Pharmaceutical Description and Business Overview
6.6.3 Simcere Pharmaceutical Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.4.4 Simcere Pharmaceutical Platinum-based Antineoplastic Product Portfolio
6.7.5 Simcere Pharmaceutical Recent Developments/Updates
6.8 Abbvie
6.8.1 Abbvie Corporation Information
6.8.2 Abbvie Description and Business Overview
6.8.3 Abbvie Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.8.4 Abbvie Platinum-based Antineoplastic Product Portfolio
6.8.5 Abbvie Recent Developments/Updates
6.9 Novartis
6.9.1 Novartis Corporation Information
6.9.2 Novartis Description and Business Overview
6.9.3 Novartis Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.9.4 Novartis Platinum-based Antineoplastic Product Portfolio
6.9.5 Novartis Recent Developments/Updates
6.10 GSK
6.10.1 GSK Corporation Information
6.10.2 GSK Description and Business Overview
6.10.3 GSK Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.10.4 GSK Platinum-based Antineoplastic Product Portfolio
6.10.5 GSK Recent Developments/Updates
6.11 MSD
6.11.1 MSD Corporation Information
6.11.2 MSD Platinum-based Antineoplastic Description and Business Overview
6.11.3 MSD Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.11.4 MSD Platinum-based Antineoplastic Product Portfolio
6.11.5 MSD Recent Developments/Updates
6.12 Hengrui Medicine
6.12.1 Hengrui Medicine Corporation Information
6.12.2 Hengrui Medicine Platinum-based Antineoplastic Description and Business Overview
6.12.3 Hengrui Medicine Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.12.4 Hengrui Medicine Platinum-based Antineoplastic Product Portfolio
6.12.5 Hengrui Medicine Recent Developments/Updates
6.13 Hansoh Pharmaceutical Group
6.13.1 Hansoh Pharmaceutical Group Corporation Information
6.13.2 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview
6.13.3 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.13.4 Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.13.5 Hansoh Pharmaceutical Group Recent Developments/Updates
6.14 ChiTaiTianQing Pharmaceutical Group
6.14.1 ChiTaiTianQing Pharmaceutical Group Corporation Information
6.14.2 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview
6.14.3 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.14.4 ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.14.5 ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates
6.15 CSPC Pharmaceutical Group
6.15.1 CSPC Pharmaceutical Group Corporation Information
6.15.2 CSPC Pharmaceutical Group Platinum-based Antineoplastic Description and Business Overview
6.15.3 CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales, Revenue and Gross Margin (2024-2024)
6.15.4 CSPC Pharmaceutical Group Platinum-based Antineoplastic Product Portfolio
6.15.5 CSPC Pharmaceutical Group Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Platinum-based Antineoplastic Industry Chain Analysis
7.2 Platinum-based Antineoplastic Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Platinum-based Antineoplastic Production Mode & Process
7.4 Platinum-based Antineoplastic Sales and Marketing
7.4.1 Platinum-based Antineoplastic Sales Channels
7.4.2 Platinum-based Antineoplastic Distributors
7.5 Platinum-based Antineoplastic Customers
8 Platinum-based Antineoplastic Market Dynamics
8.1 Platinum-based Antineoplastic Industry Trends
8.2 Platinum-based Antineoplastic Market Drivers
8.3 Platinum-based Antineoplastic Market Challenges
8.4 Platinum-based Antineoplastic Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2034) & (US$ Million)
Table 2. Global Platinum-based Antineoplastic Market Value Comparison by Application (2024-2034) & (US$ Million)
Table 3. Global Platinum-based Antineoplastic Market Competitive Situation by Manufacturers in 2022
Table 4. Global Platinum-based Antineoplastic Sales (Units) of Key Manufacturers (2024-2024)
Table 5. Global Platinum-based Antineoplastic Sales Market Share by Manufacturers (2024-2024)
Table 6. Global Platinum-based Antineoplastic Revenue (US$ Million) by Manufacturers (2024-2024)
Table 7. Global Platinum-based Antineoplastic Revenue Share by Manufacturers (2024-2024)
Table 8. Global Market Platinum-based Antineoplastic Average Price (US$/Unit) of Key Manufacturers (2024-2024)
Table 9. Global Key Players of Platinum-based Antineoplastic, Industry Ranking, 2021 VS 2022 VS 2024
Table 10. Global Key Manufacturers of Platinum-based Antineoplastic, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Platinum-based Antineoplastic, Product Type & Application
Table 12. Global Key Manufacturers of Platinum-based Antineoplastic, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Platinum-based Antineoplastic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Platinum-based Antineoplastic as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Table 17. Global Platinum-based Antineoplastic Sales by Region (2024-2024) & (Units)
Table 18. Global Platinum-based Antineoplastic Sales Market Share by Region (2024-2024)
Table 19. Global Platinum-based Antineoplastic Sales by Region (2024-2034) & (Units)
Table 20. Global Platinum-based Antineoplastic Sales Market Share by Region (2024-2034)
Table 21. Global Platinum-based Antineoplastic Revenue by Region (2024-2024) & (US$ Million)
Table 22. Global Platinum-based Antineoplastic Revenue Market Share by Region (2024-2024)
Table 23. Global Platinum-based Antineoplastic Revenue by Region (2024-2034) & (US$ Million)
Table 24. Global Platinum-based Antineoplastic Revenue Market Share by Region (2024-2034)
Table 25. North America Platinum-based Antineoplastic Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 26. North America Platinum-based Antineoplastic Sales by Country (2024-2024) & (Units)
Table 27. North America Platinum-based Antineoplastic Sales by Country (2024-2034) & (Units)
Table 28. North America Platinum-based Antineoplastic Revenue by Country (2024-2024) & (US$ Million)
Table 29. North America Platinum-based Antineoplastic Revenue by Country (2024-2034) & (US$ Million)
Table 30. Europe Platinum-based Antineoplastic Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 31. Europe Platinum-based Antineoplastic Sales by Country (2024-2024) & (Units)
Table 32. Europe Platinum-based Antineoplastic Sales by Country (2024-2034) & (Units)
Table 33. Europe Platinum-based Antineoplastic Revenue by Country (2024-2024) & (US$ Million)
Table 34. Europe Platinum-based Antineoplastic Revenue by Country (2024-2034) & (US$ Million)
Table 35. Asia Pacific Platinum-based Antineoplastic Revenue by Region: 2024 VS 2022 VS 2034 (US$ Million)
Table 36. Asia Pacific Platinum-based Antineoplastic Sales by Region (2024-2024) & (Units)
Table 37. Asia Pacific Platinum-based Antineoplastic Sales by Region (2024-2034) & (Units)
Table 38. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2024-2024) & (US$ Million)
Table 39. Asia Pacific Platinum-based Antineoplastic Revenue by Region (2024-2034) & (US$ Million)
Table 40. Latin America Platinum-based Antineoplastic Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 41. Latin America Platinum-based Antineoplastic Sales by Country (2024-2024) & (Units)
Table 42. Latin America Platinum-based Antineoplastic Sales by Country (2024-2034) & (Units)
Table 43. Latin America Platinum-based Antineoplastic Revenue by Country (2024-2024) & (US$ Million)
Table 44. Latin America Platinum-based Antineoplastic Revenue by Country (2024-2034) & (US$ Million)
Table 45. Middle East & Africa Platinum-based Antineoplastic Revenue by Country: 2024 VS 2022 VS 2034 (US$ Million)
Table 46. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2024-2024) & (Units)
Table 47. Middle East & Africa Platinum-based Antineoplastic Sales by Country (2024-2034) & (Units)
Table 48. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2024-2024) & (US$ Million)
Table 49. Middle East & Africa Platinum-based Antineoplastic Revenue by Country (2024-2034) & (US$ Million)
Table 50. Global Platinum-based Antineoplastic Sales (Units) by Type (2024-2024)
Table 51. Global Platinum-based Antineoplastic Sales (Units) by Type (2024-2034)
Table 52. Global Platinum-based Antineoplastic Sales Market Share by Type (2024-2024)
Table 53. Global Platinum-based Antineoplastic Sales Market Share by Type (2024-2034)
Table 54. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2024-2024)
Table 55. Global Platinum-based Antineoplastic Revenue (US$ Million) by Type (2024-2034)
Table 56. Global Platinum-based Antineoplastic Revenue Market Share by Type (2024-2024)
Table 57. Global Platinum-based Antineoplastic Revenue Market Share by Type (2024-2034)
Table 58. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2024-2024)
Table 59. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2024-2034)
Table 60. Global Platinum-based Antineoplastic Sales (Units) by Application (2024-2024)
Table 61. Global Platinum-based Antineoplastic Sales (Units) by Application (2024-2034)
Table 62. Global Platinum-based Antineoplastic Sales Market Share by Application (2024-2024)
Table 63. Global Platinum-based Antineoplastic Sales Market Share by Application (2024-2034)
Table 64. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2024-2024)
Table 65. Global Platinum-based Antineoplastic Revenue (US$ Million) by Application (2024-2034)
Table 66. Global Platinum-based Antineoplastic Revenue Market Share by Application (2024-2024)
Table 67. Global Platinum-based Antineoplastic Revenue Market Share by Application (2024-2034)
Table 68. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2024-2024)
Table 69. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2024-2034)
Table 70. Pfizer Corporation Information
Table 71. Pfizer Description and Business Overview
Table 72. Pfizer Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 73. Pfizer Platinum-based Antineoplastic Product
Table 74. Pfizer Recent Developments/Updates
Table 75. AstraZeneca Corporation Information
Table 76. AstraZeneca Description and Business Overview
Table 77. AstraZeneca Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 78. AstraZeneca Platinum-based Antineoplastic Product
Table 79. AstraZeneca Recent Developments/Updates
Table 80. Roche Corporation Information
Table 81. Roche Description and Business Overview
Table 82. Roche Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 83. Roche Platinum-based Antineoplastic Product
Table 84. Roche Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 88. Sanofi Platinum-based Antineoplastic Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 93. Bristol-Myers Squibb Platinum-based Antineoplastic Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Asta Medica GmbH Corporation Information
Table 96. Asta Medica GmbH Description and Business Overview
Table 97. Asta Medica GmbH Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 98. Asta Medica GmbH Platinum-based Antineoplastic Product
Table 99. Asta Medica GmbH Recent Developments/Updates
Table 100. Simcere Pharmaceutical Corporation Information
Table 101. Simcere Pharmaceutical Description and Business Overview
Table 102. Simcere Pharmaceutical Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 103. Simcere Pharmaceutical Platinum-based Antineoplastic Product
Table 104. Simcere Pharmaceutical Recent Developments/Updates
Table 105. Abbvie Corporation Information
Table 106. Abbvie Description and Business Overview
Table 107. Abbvie Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 108. Abbvie Platinum-based Antineoplastic Product
Table 109. Abbvie Recent Developments/Updates
Table 110. Novartis Corporation Information
Table 111. Novartis Description and Business Overview
Table 112. Novartis Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 113. Novartis Platinum-based Antineoplastic Product
Table 114. Novartis Recent Developments/Updates
Table 115. GSK Corporation Information
Table 116. GSK Description and Business Overview
Table 117. GSK Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 118. GSK Platinum-based Antineoplastic Product
Table 119. GSK Recent Developments/Updates
Table 120. MSD Corporation Information
Table 121. MSD Description and Business Overview
Table 122. MSD Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 123. MSD Platinum-based Antineoplastic Product
Table 124. MSD Recent Developments/Updates
Table 125. Hengrui Medicine Corporation Information
Table 126. Hengrui Medicine Description and Business Overview
Table 127. Hengrui Medicine Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 128. Hengrui Medicine Platinum-based Antineoplastic Product
Table 129. Hengrui Medicine Recent Developments/Updates
Table 130. Hansoh Pharmaceutical Group Corporation Information
Table 131. Hansoh Pharmaceutical Group Description and Business Overview
Table 132. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 133. Hansoh Pharmaceutical Group Platinum-based Antineoplastic Product
Table 134. Hansoh Pharmaceutical Group Recent Developments/Updates
Table 135. ChiTaiTianQing Pharmaceutical Group Corporation Information
Table 136. ChiTaiTianQing Pharmaceutical Group Description and Business Overview
Table 137. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 138. ChiTaiTianQing Pharmaceutical Group Platinum-based Antineoplastic Product
Table 139. ChiTaiTianQing Pharmaceutical Group Recent Developments/Updates
Table 140. CSPC Pharmaceutical Group Corporation Information
Table 141. CSPC Pharmaceutical Group Description and Business Overview
Table 142. CSPC Pharmaceutical Group Platinum-based Antineoplastic Sales (Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2024-2024)
Table 143. CSPC Pharmaceutical Group Platinum-based Antineoplastic Product
Table 144. CSPC Pharmaceutical Group Recent Developments/Updates
Table 145. Key Raw Materials Lists
Table 146. Raw Materials Key Suppliers Lists
Table 147. Platinum-based Antineoplastic Distributors List
Table 148. Platinum-based Antineoplastic Customers List
Table 149. Platinum-based Antineoplastic Market Trends
Table 150. Platinum-based Antineoplastic Market Drivers
Table 151. Platinum-based Antineoplastic Market Challenges
Table 152. Platinum-based Antineoplastic Market Restraints
Table 153. Research Programs/Design for This Report
Table 154. Key Data Information from Secondary Sources
Table 155. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Platinum-based Antineoplastic
Figure 2. Global Platinum-based Antineoplastic Market Value Comparison by Type (2024-2034) & (US$ Million)
Figure 3. Global Platinum-based Antineoplastic Market Share by Type in 2022 & 2034
Figure 4. Cisplatin Product Picture
Figure 5. Carboplatin Product Picture
Figure 6. Nedaplatin Product Picture
Figure 7. Oxaliplatin Product Picture
Figure 8. Lobaplatin Product Picture
Figure 9. Cycloplatin Product Picture
Figure 10. Global Platinum-based Antineoplastic Market Value Comparison by Application (2024-2034) & (US$ Million)
Figure 11. Global Platinum-based Antineoplastic Market Share by Application in 2022 & 2034
Figure 12. Combination Therapy
Figure 13. Monotherapy
Figure 14. Targeted Therapy
Figure 15. Global Platinum-based Antineoplastic Revenue, (US$ Million), 2024 VS 2022 VS 2034
Figure 16. Global Platinum-based Antineoplastic Market Size (2024-2034) & (US$ Million)
Figure 17. Global Platinum-based Antineoplastic Sales (2024-2034) & (Units)
Figure 18. Global Platinum-based Antineoplastic Average Price (US$/Unit) & (2024-2034)
Figure 19. Platinum-based Antineoplastic Report Years Considered
Figure 20. Platinum-based Antineoplastic Sales Share by Manufacturers in 2022
Figure 21. Global Platinum-based Antineoplastic Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Platinum-based Antineoplastic Players: Market Share by Revenue in 2022
Figure 23. Platinum-based Antineoplastic Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 24. Global Platinum-based Antineoplastic Market Size by Region (US$ Million): 2024 VS 2022 VS 2034
Figure 25. North America Platinum-based Antineoplastic Sales Market Share by Country (2024-2034)
Figure 26. North America Platinum-based Antineoplastic Revenue Market Share by Country (2024-2034)
Figure 27. United States Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 28. Canada Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 29. Europe Platinum-based Antineoplastic Sales Market Share by Country (2024-2034)
Figure 30. Europe Platinum-based Antineoplastic Revenue Market Share by Country (2024-2034)
Figure 31. Germany Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 32. France Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 33. U.K. Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 34. Italy Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 35. Russia Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 36. Asia Pacific Platinum-based Antineoplastic Sales Market Share by Region (2024-2034)
Figure 37. Asia Pacific Platinum-based Antineoplastic Revenue Market Share by Region (2024-2034)
Figure 38. China Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 39. Japan Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 40. South Korea Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 41. India Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 42. Australia Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 43. China Taiwan Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 44. Southeast Asia Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 45. Latin America Platinum-based Antineoplastic Sales Market Share by Country (2024-2034)
Figure 46. Latin America Platinum-based Antineoplastic Revenue Market Share by Country (2024-2034)
Figure 47. Mexico Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 48. Brazil Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 49. Argentina Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 50. Middle East & Africa Platinum-based Antineoplastic Sales Market Share by Country (2024-2034)
Figure 51. Middle East & Africa Platinum-based Antineoplastic Revenue Market Share by Country (2024-2034)
Figure 52. Turkey Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 53. Saudi Arabia Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 54. UAE Platinum-based Antineoplastic Revenue Growth Rate (2024-2034) & (US$ Million)
Figure 55. Global Sales Market Share of Platinum-based Antineoplastic by Type (2024-2034)
Figure 56. Global Revenue Market Share of Platinum-based Antineoplastic by Type (2024-2034)
Figure 57. Global Platinum-based Antineoplastic Price (US$/Unit) by Type (2024-2034)
Figure 58. Global Sales Market Share of Platinum-based Antineoplastic by Application (2024-2034)
Figure 59. Global Revenue Market Share of Platinum-based Antineoplastic by Application (2024-2034)
Figure 60. Global Platinum-based Antineoplastic Price (US$/Unit) by Application (2024-2034)
Figure 61. Platinum-based Antineoplastic Value Chain
Figure 62. Platinum-based Antineoplastic Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed